LT2894162T - Su augliu siejamų antigenų identifikavimas diagnostikai ir gydymui - Google Patents

Su augliu siejamų antigenų identifikavimas diagnostikai ir gydymui

Info

Publication number
LT2894162T
LT2894162T LTEP15153951.7T LT15153951T LT2894162T LT 2894162 T LT2894162 T LT 2894162T LT 15153951 T LT15153951 T LT 15153951T LT 2894162 T LT2894162 T LT 2894162T
Authority
LT
Lithuania
Prior art keywords
tumor
diagnosis
therapy
identification
associated antigens
Prior art date
Application number
LTEP15153951.7T
Other languages
English (en)
Inventor
Ugur Sahin
Özlem TÜRECI
Michael Koslowski
Dirk Usener
Original Assignee
Ganymed Pharmaceuticals Gmbh
Johannes Gutenberg-Universität Mainz, Vertreten Durch Den Präsidenten
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ganymed Pharmaceuticals Gmbh, Johannes Gutenberg-Universität Mainz, Vertreten Durch Den Präsidenten filed Critical Ganymed Pharmaceuticals Gmbh
Publication of LT2894162T publication Critical patent/LT2894162T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
LTEP15153951.7T 2005-09-12 2006-09-06 Su augliu siejamų antigenų identifikavimas diagnostikai ir gydymui LT2894162T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20050019786 EP1762575A1 (en) 2005-09-12 2005-09-12 Identification of tumor-associated antigens for diagnosis and therapy

Publications (1)

Publication Number Publication Date
LT2894162T true LT2894162T (lt) 2018-04-10

Family

ID=35285406

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP15153951.7T LT2894162T (lt) 2005-09-12 2006-09-06 Su augliu siejamų antigenų identifikavimas diagnostikai ir gydymui

Country Status (21)

Country Link
US (5) US20090202530A1 (lt)
EP (14) EP1762575A1 (lt)
JP (5) JP6037593B2 (lt)
KR (2) KR101359697B1 (lt)
CN (1) CN101305020B (lt)
AU (1) AU2006291717B2 (lt)
BR (1) BRPI0616827A2 (lt)
CA (2) CA2820201C (lt)
CY (3) CY1114661T1 (lt)
DK (3) DK1924600T3 (lt)
ES (4) ES2535500T3 (lt)
HK (3) HK1118840A1 (lt)
HR (3) HRP20131047T1 (lt)
HU (1) HUE037307T2 (lt)
LT (1) LT2894162T (lt)
PL (3) PL2433954T3 (lt)
PT (3) PT2894162T (lt)
RS (3) RS57080B1 (lt)
RU (2) RU2485974C2 (lt)
SI (3) SI2894162T1 (lt)
WO (1) WO2007031222A2 (lt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
AU2013206613B2 (en) * 2005-09-12 2017-03-02 Biontech Ag Identification of tumor-associated antigens for diagnosis and therapy
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
EP1970384A1 (en) 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP2060583A1 (en) * 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
AU2016201637B2 (en) * 2007-10-23 2017-05-25 Biontech Ag Identification of tumor-associated markers for diagnosis and therapy
AU2015205868B2 (en) * 2008-09-16 2017-04-27 Ganymed Pharmaceuticals Ag Monoclonal antibodies for treatment of cancer
EP2166021A1 (en) * 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP2371864A1 (en) 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
US9061066B2 (en) * 2010-06-04 2015-06-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Immunoadjuvant compounds and uses thereof
DK3892295T3 (da) 2011-05-24 2023-05-15 BioNTech SE Individualiserede vacciner mod cancer
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
WO2014082729A1 (en) 2012-11-28 2014-06-05 Biontech Ag Individualized vaccines for cancer
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
CA2938821A1 (en) 2014-02-07 2015-08-13 Dong Wha Pharm. Co., Ltd. Anticancer adjuvant composition containing rip3 expression promoter as active ingredient, method for screening for anticancer adjuvant enhancing sensitivity of anticancer drug by promoting rip3 expression, and method for monitoring sensitivity of anticancer drug
CN107076762B (zh) 2014-09-10 2021-09-10 豪夫迈·罗氏有限公司 免疫原性突变体肽筛选平台
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
RU2620306C2 (ru) * 2015-01-15 2017-05-24 Олег Викторович Бухтояров Способ прогнозирования рецидива злокачественного опухолевого заболевания
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
RU2018101225A (ru) * 2015-06-16 2019-07-16 Тарговакс Аса Мутированные фрагменты белка ras
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
KR20180107102A (ko) 2015-12-16 2018-10-01 그릿스톤 온콜로지, 인코포레이티드 신생항원 동정, 제조, 및 용도
WO2017127716A1 (en) 2016-01-22 2017-07-27 Temple University-Of The Commonwealth System Of Higher Education Protein quantification by near infrared spectral imaging
CN107266552B (zh) * 2016-03-30 2022-02-08 香雪生命科学技术（广东）有限公司 源自于prame的肿瘤抗原短肽
KR102344619B1 (ko) 2016-05-20 2021-12-31 아란세오 네덜란즈 비.브이. 고무 조성물
DE102016115246C5 (de) * 2016-08-17 2018-12-20 Immatics Biotechnologies Gmbh Neue t-zellrezeptoren und deren verwendung in immuntherapie
CN108250289B (zh) * 2016-12-28 2021-10-08 香雪生命科学技术（广东）有限公司 源自于mage b6的肿瘤抗原短肽
TWI676483B (zh) * 2017-08-06 2019-11-11 強普生技股份有限公司 醫藥套組及其用途
KR20200087143A (ko) 2017-10-10 2020-07-20 그릿스톤 온콜로지, 인코포레이티드 핫스팟을 이용한 신생항원 동정
AU2018373154A1 (en) 2017-11-22 2020-07-02 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
JP7082556B2 (ja) 2018-09-28 2022-06-08 三和シヤッター工業株式会社 シャッター装置

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
PL174494B1 (pl) * 1992-11-13 1998-08-31 Idec Pharma Corp Kompozycja farmaceutyczna do leczenia chłoniaka z limfocytów B i sposób wytwarzania kompozycji farmaceutycznej do leczenia chłoniaka z limfocytów B
US5744585A (en) * 1995-03-16 1998-04-28 Medenica; Rajko D. Human monoclonal antibody against lung carcinoma
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5677139A (en) 1995-04-21 1997-10-14 President And Fellows Of Harvard College In vitro differentiation of CD34+ progenitor cells into T lymphocytes
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US20020065394A1 (en) * 1998-03-18 2002-05-30 Kenneth Jacobs Secreted proteins and polynucleotides encoding them
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9826143D0 (en) 1998-11-27 1999-01-20 Ludwig Inst Cancer Res Tumour rejection antigens
ATE219687T1 (de) * 1999-01-13 2002-07-15 Igeneon Krebs Immuntherapie Verwendung von antikörpern zur vakzinierung gegen krebs
US6943235B1 (en) * 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer
NZ553687A (en) 2000-03-30 2010-03-26 Whitehead Biomedical Inst RNA sequence-specific mediators of RNA interference
US6974667B2 (en) * 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
US20020192748A1 (en) * 2000-07-18 2002-12-19 Luca Rastelli Novel polynucleotides and polypeptides encoded thereby
EA013564B1 (ru) 2000-08-03 2010-06-30 Терапеутик Хьюман Поликлоналз Инк. Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
MXPA03004793A (es) 2000-11-30 2004-12-03 Medarex Inc Roedores transgenicos transcromosomales para elaborar anticuerpos humnanos.
US20020177547A1 (en) * 2001-01-16 2002-11-28 Karin Molling Pharmaceutical compositions for treating or preventing cancer
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
CA2448146A1 (en) * 2001-05-25 2002-12-05 Incyte Genomics, Inc. Secreted proteins
WO2003016475A2 (en) * 2001-08-14 2003-02-27 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
WO2003075014A2 (en) 2002-03-06 2003-09-12 Oxford Glycosciences (Uk) Ltd Protein-protein interactions in human tumours involving bcmp-7 and bcmp-11
WO2003102159A2 (en) * 2002-06-04 2003-12-11 Curagen Corporation Novel proteins and nucleic acids encoding same
US7053201B2 (en) * 2002-08-30 2006-05-30 National Defense Medical Center Nucleic acid molecules and polypeptides related to h-ADAM7
TW200413539A (en) * 2002-09-30 2004-08-01 Oncotherapy Science Inc Genes and polypeptides relating to prostate cancers
AU2003301445A1 (en) 2002-10-17 2004-05-04 Genmab A/S Human monoclonal antibodies against cd20
WO2004043232A2 (en) * 2002-11-06 2004-05-27 Sequenom, Inc. Methods for identifying risk of melanoma and treatments thereof
US7235359B2 (en) * 2003-01-17 2007-06-26 The Chinese University Of Hong Kong Method for diagnosing preeclampsia by detecting hCRH mRNA
EP1592811A2 (en) * 2003-02-11 2005-11-09 Wyeth Methods for monitoring drug activities in vivo
WO2005049806A2 (en) * 2003-03-14 2005-06-02 Nuvelo, Inc. Novel nucleic acids and polypeptides
US20050255114A1 (en) * 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
RU2256924C2 (ru) * 2003-09-03 2005-07-20 Торопова Надежда Ефимовна Способ дифференциальной диагностики злокачественных опухолей простаты
WO2005079490A2 (en) * 2004-02-13 2005-09-01 Nuvelo, Inc. Methods of therapy and diagnosis using targeting of cells that express steap2 polypeptides
CN1663603A (zh) * 2004-03-02 2005-09-07 北京大学 一种肿瘤－胎盘抗原蛋白及其dna在肿瘤治疗中的应用
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
EP1970384A1 (en) 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP2166021A1 (en) 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
CN107028969A (zh) 2009-02-20 2017-08-11 加尼梅德药物公司 用于癌症诊断和治疗的方法和组合物
EP2221063A1 (en) 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
EP2371864A1 (en) 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer

Also Published As

Publication number Publication date
PL2894162T3 (pl) 2018-06-29
EP1924600B1 (en) 2013-08-28
EP2433960A2 (en) 2012-03-28
RS53988B1 (en) 2015-10-30
RU2013113439A (ru) 2014-10-10
EP2433962B1 (en) 2015-03-25
RU2485974C2 (ru) 2013-06-27
EP2433961A2 (en) 2012-03-28
EP2966082A1 (en) 2016-01-13
ES2535500T3 (es) 2015-05-12
EP2433955A3 (en) 2012-07-04
EP2433956A3 (en) 2012-07-04
EP2433954B1 (en) 2015-02-25
HK1211606A1 (en) 2016-05-27
US20090202530A1 (en) 2009-08-13
JP2013136579A (ja) 2013-07-11
RU2008114318A (ru) 2009-10-20
JP6037593B2 (ja) 2016-12-07
CN101305020A (zh) 2008-11-12
EP2894162A1 (en) 2015-07-15
SI2894162T1 (en) 2018-05-31
US20110189179A1 (en) 2011-08-04
RU2644686C2 (ru) 2018-02-13
EP2433954A2 (en) 2012-03-28
PL2433954T3 (pl) 2015-07-31
EP2433960B1 (en) 2015-03-04
PT2433954E (pt) 2015-06-02
JP2015120691A (ja) 2015-07-02
JP5750433B2 (ja) 2015-07-22
JP2016102116A (ja) 2016-06-02
EP1924600A2 (en) 2008-05-28
KR101359697B1 (ko) 2014-02-07
AU2006291717A1 (en) 2007-03-22
EP2433961A3 (en) 2012-06-27
EP2966082B1 (en) 2017-08-30
DK1924600T3 (da) 2013-11-11
WO2007031222A2 (en) 2007-03-22
SI2433954T1 (sl) 2015-06-30
EP2433955A2 (en) 2012-03-28
EP1762575A1 (en) 2007-03-14
EP2433958A3 (en) 2012-07-04
EP2433960A3 (en) 2012-07-04
HRP20131047T1 (hr) 2013-12-06
JP2009507868A (ja) 2009-02-26
SI1924600T1 (sl) 2013-12-31
AU2006291717B2 (en) 2013-06-06
CA2620712A1 (en) 2007-03-22
BRPI0616827A2 (pt) 2011-07-05
EP2433962A3 (en) 2012-07-04
HRP20150432T1 (hr) 2015-09-25
JP5913547B2 (ja) 2016-04-27
DK2433954T3 (en) 2015-05-04
EP2433958B1 (en) 2015-02-25
EP2902412B1 (en) 2018-02-21
KR20130121198A (ko) 2013-11-05
PT1924600E (pt) 2013-11-18
DK2894162T3 (en) 2018-04-16
PL1924600T3 (pl) 2014-01-31
EP2433957A2 (en) 2012-03-28
HK1118840A1 (en) 2009-02-20
CY1114661T1 (el) 2016-10-05
ES2532410T3 (es) 2015-03-26
ES2664386T3 (es) 2018-04-19
EP2902412A1 (en) 2015-08-05
US9919036B2 (en) 2018-03-20
RS57080B1 (sr) 2018-06-29
CA2820201C (en) 2018-07-17
EP2433954B8 (en) 2015-05-13
RS53009B (en) 2014-04-30
PT2894162T (pt) 2018-04-02
US20140017254A1 (en) 2014-01-16
CA2820201A1 (en) 2007-03-22
EP2433956A2 (en) 2012-03-28
EP2894162B1 (en) 2018-01-03
EP2433957A3 (en) 2012-07-04
HK1168608A1 (en) 2013-01-04
CY1120096T1 (el) 2018-12-12
CN101305020B (zh) 2015-09-02
EP2433962A2 (en) 2012-03-28
EP2433958A2 (en) 2012-03-28
ES2434945T3 (es) 2013-12-18
EP2433954A3 (en) 2012-07-04
JP6196338B2 (ja) 2017-09-13
HUE037307T2 (hu) 2018-08-28
KR20080052664A (ko) 2008-06-11
JP2016166175A (ja) 2016-09-15
US8975375B2 (en) 2015-03-10
EP2433959A2 (en) 2012-03-28
US20170080068A1 (en) 2017-03-23
CY1116951T1 (el) 2017-04-05
US20150197576A1 (en) 2015-07-16
HRP20180507T1 (hr) 2018-05-04
EP2433959A3 (en) 2012-06-27
WO2007031222A3 (en) 2007-07-26

Similar Documents

Publication Publication Date Title
HK1211606A1 (en) Identification of tumor-associated antigens for diagnosis and therapy
EP1994181A4 (en) IDENTIFICATION AND USE OF NOVOPEPTIDES FOR THE TREATMENT OF CANCER
IL225386A0 (en) Diagnosis and treatment of cancer using anti-ereg antibody
EP2050466A4 (en) DIAGNOSIS AND TREATMENT OF CANCER USING ANTI-DESMOGLEIN ANTIBODY-3
EP1814909A4 (en) USE OF AIMP2DX2 FOR THE DIAGNOSIS AND TREATMENT OF CANCER
EP1811844A4 (en) METHOD FOR THE DIAGNOSIS AND TREATMENT OF CANCER
HRP20140271T1 (hr) Humana antitijela protiv bjesnoä†e i njihova uporaba
EP2216344A4 (en) DIAGNOSIS AND TREATMENT OF CANCER WITH AN ANTI-GPR49 ANTIBODY
EP2103628A4 (en) MONOCLONAL ANTIBODY ANTI-CLAUDIN 3, AND TREATMENT AND DIAGNOSIS OF CANCER USING SUCH ANTIBODY
EP1718145A4 (en) CONJUGATES FOR CANCER THERAPY AND DIAGNOSIS
IL179811A0 (en) Identification of tumors
EP1742654A4 (en) ANTI-LFL2 ANTIBODIES FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF CANCER
EP1869212A4 (en) USE OF ID4 FOR DIAGNOSIS AND TREATMENT OF CANCER
EP1937816A4 (en) CANCER DIAGNOSTIC MARKERS AND USE
HK1164767A1 (en) Compounds and methods for the treatment of cancer
EP1871166A4 (en) VACCINES AGAINST CANCER AND THERAPEUTIC METHODS
IL185900A0 (en) Compositions and methods for the diagnosis and treatment of tumor
ZA200706159B (en) Compositions and methods for the diagnosis and treatment of tumor
IL201880A0 (en) Klotho protein and related compounds for the treatment and diagnosis of cancer
GB0517599D0 (en) Means and methods of verification of entitlement and identification
GB0421917D0 (en) Cancer diagnosis and therapy
ZA200710321B (en) Compositions and methods for the diagnosis and treatment of tumor